Latest 10-K annual reports

Intuitive Machines, Inc. reported a reduced net loss in 2025, driven by strategic acquisitions and significant capital raises, as it advances its 'Build-Connect-Operate' space infrastructure strategy.

MultiSensor AI Holdings, Inc. reported a net loss of $11.7 million for 2025, a significant improvement from the prior year, while increasing active sensors on its MSAI Connect platform by 59%.

Red Cat Holdings, a U.S.-based drone and robotic solutions provider, reported significant revenue growth in 2025 driven by U.S. Army drone deliveries, alongside substantial capital raises, despite continued net losses.

BullFrog AI Holdings, Inc. reported a net loss of $6.5 million for 2025 and faces potential delisting from Nasdaq due to non-compliance with equity and minimum bid price requirements, despite initial revenue generation and strategic collaborations.

Harvard Apparatus Regenerative Technology, Inc. reports a significant accumulated deficit and auditor's going concern qualification, alongside delays in patient recruitment for its pivotal esophageal regeneration clinical trial, despite revenue growth in its consumer health segment.

electroCore reports increased 2025 revenue driven by prescription products and general wellness offerings, alongside continued net losses and a CEO retirement, raising going concern doubts.

The Eastern Company filed an amended annual report to include omitted exhibits, revealing a significant 57% decline in net income for fiscal year 2025 amidst lower sales and higher material costs.

Zion Oil & Gas reports continued net losses and going concern doubt for 2025, while advancing its Megiddo Valleys exploration in Israel amidst regional conflicts and significant capital requirements.

Westwater Resources' 2025 annual report highlights progress on its Kellyton Graphite Plant and Coosa Graphite Deposit, alongside financial challenges and a terminated offtake agreement.

Five Below, Inc. announced robust financial results for fiscal year 2025, driven by significant sales increases and continued store expansion, while outlining plans for future growth.

SailPoint, Inc. reported significant growth in subscription revenue, particularly SaaS, following its successful IPO and strategic investments in AI-driven identity security solutions for the fiscal year ended January 31, 2026.

Relmada Therapeutics, Inc. has undergone a significant strategic shift, terminating prior drug programs to focus on two new clinical-stage candidates, NDV-01 and sepranolone, while securing substantial new financing.

Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envu in plaque psoriasis, while also securing a $300 million at-the-market equity offering facility.

Terra Property Trust reported a reduced net loss in 2025 but faces significant debt maturities and declining revenues, prompting strategic liquidity explorations.

CSLM Digital Asset Acquisition Corp III, a blank check company, reported its 2025 annual results, highlighting its successful IPO and a non-binding letter of intent for a business combination with First Digital Group Ltd.

Crawford & Company filed an amended annual report for fiscal year 2025, revealing a significant drop in net income and revenues, alongside a CEO transition and a new restructuring plan.

Ollie's Bargain Outlet Holdings, Inc. reported significant financial growth for fiscal year 2025, driven by new store expansion and increased comparable store sales.

Intellicheck, Inc. reported a significant turnaround, achieving net income of $1.273 million for the fiscal year ended December 31, 2025, driven by a 13% increase in SaaS revenue.

Burlington Stores, Inc. reported significant financial improvements in Fiscal Year 2025, with net sales up 8.8% and net income increasing to $610.2 million, driven by new store expansion and enhanced operational efficiency.

Eton Pharmaceuticals reports significant revenue growth in 2025 driven by product sales, despite an increased net loss and ongoing R&D investments.

Biofrontera Inc. reported an 11.8% revenue increase and reduced net loss in 2025, driven by a strategic acquisition and cost efficiencies, despite facing substantial doubt about its ability to continue as a going concern.

Assembly Biosciences reports positive clinical data for multiple programs and Gilead exercises its option to license the HPI program for recurrent genital herpes, significantly boosting revenue and liquidity.

RCI Hospitality Holdings, Inc. reported a 5.5% revenue decrease to $279.4 million for fiscal year 2025, alongside a significant increase in diluted EPS to $1.23, while addressing material weaknesses in internal controls and ongoing legal challenges.

Zura Bio Limited, a clinical-stage biotechnology company, reported a net loss of $68.7 million for the fiscal year ended December 31, 2025, while successfully raising $135.1 million in a February 2026 equity offering to fund ongoing clinical trials.

Kohl's reported a 4% net sales decrease in fiscal year 2025, but saw improved profitability and cash flow, while providing a cautious outlook for fiscal year 2026.

Sprinklr's annual report reveals an 8% revenue increase and strong cash flow, but net income plunged and customer counts declined amidst significant restructuring and ongoing legal challenges.

Rubrik, Inc. reports significant revenue and subscription ARR growth for fiscal year 2026, driven by its Zero Trust Data Security platform and new AI offerings, despite ongoing operating losses.

Snail, Inc. reported a significant net loss of $27.2 million for fiscal year 2025, a sharp decline from the prior year's net income, alongside a revenue decrease and a Nasdaq deficiency notice.

ONE Group Hospitality reported a significant net loss in 2025, primarily due to a non-cash tax valuation allowance, despite revenue growth driven by the Benihana acquisition.

Genelux Corporation reported increased net losses for 2025 but extended its cash runway into the first quarter of 2027 following recent capital raises, while advancing its oncolytic viral immunotherapy pipeline.